SCHEMBL371079

SCHEMBL371079

C=CC[C@@](C)(N)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503376 1.00
SCHEMBL503383 1.00
SCHEMBL500669 0.98 GGT1 (0.42)
Water SCHEMBL27459592 0.98 GGT1 (0.42)
Hydrochloric Acid SCHEMBL74583 0.98 GGT1 (0.42)
Water SCHEMBL7508586 0.98 GGT1 (0.42)
Water SCHEMBL18669981 0.88 TSHR (0.39)
SCHEMBL5488304 0.79 HTT (0.33)
Bicarbonate SCHEMBL8039493 0.78 HTT (0.38)
SCHEMBL2481158 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016943-A1 SYNTHETIC DNA BINDING DOMAINS AND USES THEREOF THE UNIVERSITY OF CHICAGO (US) 2024-01-18 US claimed
EP-4251642-A1 SYNTHETIC DNA BINDING DOMAINS AND USES THEREOF The University of Chicago (US) 2023-10-04 EP claimed
WO-2022115595-A1 SYNTHETIC DNA BINDING DOMAINS AND USES THEREOF THE UNIVERSITY OF CHICAGO (US) 2022-06-02 WO claimed
EP-3698810-A1 STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE Dana Farber Cancer Institute, Inc. (US) 2020-08-26 EP claimed
EP-3698811-A1 STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE Dana Farber Cancer Institute, Inc. (US) 2020-08-26 EP claimed
WO-2018112226-A1 SHARPIN-BASED POLYPEPTIDES AND THEIR USES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-06-21 WO claimed
EP-0833626-B1 MONO- AND DISULFO-SUBSTITUTED ANTHRAQUINONES AND THEIR USE FOR THE TREATMENT OF BONE MATRIX DISORDERS H GEN B V (NL) 2003-03-05 EP claimed
CN-120202211-A Cyclic compounds having selective KRAS inhibition over HRAS and NRAS 中外制药株式会社 2025-06-24 CN disclosed
CN-119866342-A Cyclic peptides for capturing interleukin-1 beta 默沙东有限责任公司 2025-04-22 CN disclosed
CN-119731195-A Cyclic compounds having selective inhibition of KRAS over HRAS and NRAS 中外制药株式会社 2025-03-28 CN disclosed
EP-4504732-A2 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF University of Connecticut (US) 2025-02-12 EP disclosed
CN-118879592-A Unnatural base pair compositions and methods of use 斯克利普斯研究所 2024-11-01 CN disclosed
EP-4399220-A1 ANTIVIRAL STRUCTURALLY-STAPLED SARS-COV-2 PEPTIDE- CHOLESTEROL CONJUGATES AND USES THEREOF Dana-Farber Cancer Institute, Inc. (US) 2024-07-17 EP disclosed
US-6780573-B1 ADEQUATE DIFFUSION RESISTANCE WITHOUT BALLAST; MINIMIZED SPEED LOSS; GREATER INTERIMAGE; EFFICIENT REMOVAL EASTMAN KODAK COMPANY 2004-08-24 US disclosed
US-20030167129-A1 Binding compounds and methods for identifying binding compounds IWA, LLC 2003-09-04 US disclosed
EP-0833626-B1 MONO- AND DISULFO-SUBSTITUTED ANTHRAQUINONES AND THEIR USE FOR THE TREATMENT OF BONE MATRIX DISORDERS H GEN B V (NL) 2003-03-05 EP disclosed
US-20030018438-A1 Binding compounds and methods for identifying binding compounds IWA, LLC 2003-01-23 US disclosed
WO-2002057313-A2 RECEPTOR-BINDING COMPOUNDS AND METHODS FOR IDENTIFYING THEM CONSENSUS PHARMACEUTICALS, INC. (US) 2002-07-25 WO disclosed
US-5268476-A Substituted 10bH-oxazolo[3,2-c] [1,3] benzoxazine-2(3H), 5-diones ABBOTT LABORATORIES (US) 1993-12-07 US disclosed
US-5153358-A Process for the preparation of alpha-alkylated alpha-amino acids and alpha-halogenated alpha-amino acids ABBOTT LABORATORIES (US) 1992-10-06 US disclosed